Agricultural giant Bayer can’t block an Australian herbicide maker from trade marking ‘Preceed’ for its products, with a delegate from the Trade Marks Office finding the mark was not deceptively similar to Bayer’s ‘Precept’ weed killer mark.
The international company behind the Vagisil feminine hygiene brand has lost its bid to stop a European competitor from registering Vagisan as a trade mark in Australia.
IP boutique Griffith Hack will soon have around 80 practicing lawyers when it absorbs Australia’s oldest specialist intellectual property firm Watermark next year.
UK biopharmaceutical company Kymab may attack experiments done by US biotechnology giant Regeneron creating genetically modified mice with splices of human genomes, as it defends its proposed patent for a human rat.
Kraft Foods can amend its patent application for a chocolate that doesn’t melt in the summer months, after a delegate found many of the claims of the patent lacked clarity and support.
Chemical giant BASF has dropped a lawsuit against Lubrizol Corporation challenging proposed amendments to a fuel additive patent.
Generic drug maker Juno Pharmaceuticals and US-based Millennium Pharmaceuticals have reached an in-principle settlement in their trans-Pacific dispute over two patents covering breakthrough anti-cancer medication Velcade.
US biotechnology company Regeneron Pharmaceuticals has filed a Federal Court challenge after losing its opposition to a patent application by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.
The Australian federal government’s proposed legislation to abolish the innovation patent system, Australia’s second tier patent system, was introduced into parliament on July 25. Here, Griffith Hack’s Dr Malcolm Lyons and Dr Justin Sweetman tell you what you need to know about the Intellectual Property Laws Amendment (Productivity Commission Response Part 2 and Other Measures) Bill 2019.
US biotechnology firm Regeneron Pharmaceuticals has lost its opposition to a proposed patent by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.